Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
404 participants
INTERVENTIONAL
2020-12-11
2026-12-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
NCT05834738
Atrasentan in Patients With Proteinuric Glomerular Diseases
NCT04573920
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
NCT04578834
A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy
NCT04663204
A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria
NCT04456816
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Additional subjects receiving a stable dose of SGLT2i will be enrolled to the study. Enrollment in this SGLT2i stable stratum will be in accordance with local regulations in regions that prescribe SGLT2i and will be independent of the 320 subjects enrolled for the primary and secondary analyses.
The primary objective of the study is to evaluate the effect of atrasentan versus placebo on proteinuria as measured by UPCR. Secondary and tertiary objectives include evaluating the change in kidney function over time as measured by eGFR, safety and tolerability, as well as quality of life.
Subjects will have assessments of safety and efficacy over 2 ½ years. To facilitate study participation over this time period, where allowed by local regulations, options for remote study visits using telemedicine and home health may be offered.
Subjects who complete treatment through Week 132 and complete the double-blinded portion of the study may be eligible to enroll in the open label extension of the study to receive atrasentan 0.75 mg daily for up to 48 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atrasentan
Double-blind Period: Once daily oral administration of 0.75 mg atrasentan for 132 weeks.
Open-label Extension Period: Once daily oral administration of 0.75 mg atrasentan for 48 weeks after completion of 132 weeks on atrasentan or placebo.
Atrasentan
Film-coated tablet
Placebo
Double-blind Period: Once daily oral administration of placebo for 132 weeks
Placebo
Film-coated tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atrasentan
Film-coated tablet
Placebo
Film-coated tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Biopsy-proven IgA nephropathy.
* Receiving a maximally tolerated dose of RAS inhibitor therapy (ACEi or ARB) that has been stable for at least 12 weeks. Exceptions from this requirement will be made for subjects who are unable to tolerate RAS inhibitor therapy.
* Total urine protein ≥1 g/day as measured via 24-hour urine collection by central laboratory at Screening.
* eGFR of at least 30 mL/min/1.73 m\^2 at Screening based on the CKD-EPI equation.
* Willing and able to provide informed consent and comply with all study requirements.
* SGLT2i Stable Stratum Only - Receiving a stable dose of an SGLT2i (per Investigator choice) in addition to a maximally tolerated and optimized dose of a RAS inhibitor that has been stable for at least 12 weeks prior to Screening.
* All fertile men and WOCBP who engage in heterosexual intercourse must be willing to abide with highly effective forms of contraception, as specified in the protocol, throughout the study and for 1 month afterward. In WOCBP, use of contraceptive agents must have been started at least 1 month prior to Baseline.
Open-Label Period:
* Willing and able to provide informed consent and comply with all OL extension study visits and study procedures.
* Completed treatment through Week 132 and completed the Week 136 visit.
* All fertile men and WOCBP who engage in heterosexual intercourse must be willing to abide with highly effective forms of contraception, as specified in the protocol, throughout the study and for 1 month afterward. In WOCBP, use of contraceptive agents must have been continued after completing the double-blind portion of the study.
Exclusion Criteria
* Concurrent diagnosis of another cause of chronic kidney disease including diabetic kidney disease or another primary glomerulopathy.
* Clinical diagnosis of nephrotic syndrome.
* BNP value of \> 200 pg/mL at Screening.
* Platelet count \<80,000 per μL at Screening.
* History of organ transplantation (subjects with history of corneal transplant are not excluded).
* Use of systemic immunosuppressant medications.
* Hemoglobin below 9 g/dL at Screening or prior history of blood transfusion for anemia within 3 months of Screening.
Open-label period:
* eGFR \< 25 mL/min/1.73m\^2 or evidence of rapidly decreasing eGFR, including unrecovered acute kidney injury or expected to require renal replacement therapy within 3 months
* BNP value of \> 200 pg/mL at OL Screening.
* Platelet count \< 80,000 per μL at OL Screening.
* Hemoglobin below 9 g/dL at OL screening or prior history of blood transfusion for anemia within 3 months of OL Screening.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinook Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Comprehensive Research Institute
Alhambra, California, United States
Kidney Disease Medical Group
Glendale, California, United States
Stanford University
Stanford, California, United States
University of Florida
Gainesville, Florida, United States
GA Nephrology Associates
Lawrenceville, Georgia, United States
NANI Research, LLC
Hinsdale, Illinois, United States
NANI Research, LLC
Fort Wayne, Indiana, United States
University of Louisville Physicians- Kidney Disease Program
Louisville, Kentucky, United States
Tufts Medical Center
Boston, Massachusetts, United States
Intermed Consultants
Minneapolis, Minnesota, United States
Pelican Point Dialysis - DaVita Clinical Research
Las Vegas, Nevada, United States
Capital District Renal Physicians
Clifton Park, New York, United States
Mountain Kidney and Hypertension Associates
Asheville, North Carolina, United States
Brookview Hills Research Associates, LLC
Winston-Salem, North Carolina, United States
Lehigh Valley Hospital
Bethlehem, Pennsylvania, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Liberty Research Center
Dallas, Texas, United States
El Paso Kidney Specialists
El Paso, Texas, United States
Nephrology Associates Of Northern Virginia
Fairfax, Virginia, United States
Swedish Health Services
Seattle, Washington, United States
Centro Médico Ce.Re.Ca
San Luis, San Luis Province, Argentina
CEMIC
Buenos Aires, , Argentina
Hospital Britanico de Buenos Aires
Buenos Aires, , Argentina
Clinica de Nefrologia Urologia y Enf. Cardiovasculares
Santa Fe, , Argentina
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Melbourne Renal Research Group
Reservoir, Victoria, Australia
Sunshine Hospital
Saint Albans, Victoria, Australia
Box Hill Hospital
Box Hill, , Australia
Royal Brisbane & Women's Hospital
Brisbane, , Australia
Monash Medical Centre
Clayton, , Australia
Renal Research
Gosford, , Australia
Nepean Hospital
Kingswood, , Australia
Instituto Pró-Renal Brasil
Curitiba, Paraná, Brazil
Hospital das Clínicas Universidade Federal de Minas Gerais - UFMG
Belo Horizonte, , Brazil
Centro de Pesquisa Clinica do Brasil
Brasília, , Brazil
Santa Casa de Misericordia de Porto Alegre
Porto Alegre, , Brazil
Praxis Pesquisa Médica
Santo André, , Brazil
Hospital das Clinicas da Faculdade de Medicina da USP
São Paulo, , Brazil
Hospital do Rim Fundacao Oswaldo Ramos
São Paulo, , Brazil
London Health Sciences Centre
London, Ontario, Canada
Stephen S. Chow Medicine Professionals
Toronto, Ontario, Canada
Dongguan Tungwah Hospital
Dongguan, Dongguan, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
The First A ffliated Hospital of Baotou Medical College, Inner Mangolia University of Science and Technology
Baotou, Inner Mongolia Autonomou, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
The Affiliated Hospital of Nantong University
Nantong, Jiangsu, China
Renji Hospital Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
People's Hospital of Sichuan Province
Chengdu, Sichuan, China
The First Affiliated Hospital Xinjiang Medical University
Ürümqi, Xinjiang Uygur, China
Peking University First Hospital
Beijing, , China
Peking University People's Hospital
Beijing, , China
The Second Hospital of Jilin University
Changchun, , China
The Third Xiangya Hospital of Central South University
Changsha, , China
West China Hospital, Sichuan University
Chengdu, , China
The First Affiliated Hospital of Fujian Medical University
Fuzhou, , China
Nanfang Hospital of Southern Medical University
Guangzhou, , China
The Second Hospital of Anhui Medical University
Hefei, , China
Shandong University - Qilu Hospital
Jinan, , China
The First Affiliated Hospital of Nanchang University
Nanchang, , China
Peking University Shenzhen Hospital
Shenzhen, , China
Hospital Alma Mater de Antioquia
Medellín, Antioquia, Colombia
IPS Medicos Internistas de Caldas S.A.S
Manizales, Caldas Department, Colombia
CHU de Grenoble - Hopital Albert Michallon
Grenoble, , France
CH Emile Roux
Le Puy-en-Velay, , France
Hopital Necker
Paris, , France
CHU Saint Etienne - Hopital Nord
Saint-Priest-en-Jarez, , France
Centre Hospitalier Valenciennes
Valenciennes, , France
St. Josefs-Hospital
Cloppenburg, , Germany
Medizinische Hochschule Hannover
Hanover, , Germany
Nephrologisches Zentrum Hoyerswerda
Hoyerswerda, , Germany
Universitaetsklinikum Jena
Jena, , Germany
Nephrologisches Zentrum Villingen-Schwenningen
Villingen-Schwenningen, , Germany
Universitaetsklinikum Wuerzburg
Würzburg, , Germany
Princess Margaret Hospital
Hong Kong, , Hong Kong
The University of Hong Kong
Hong Kong, , Hong Kong
Yan Chai Hospital
Hong Kong, , Hong Kong
The Chinese University of Hong Kong
Shatin, , Hong Kong
Government Medical College
Kozhikode, Kerala, India
Sahyadri Super Speciality Hospital
Pune, Maharashtra, India
Christian Medical College
Vellore, Tamil Nadu, India
Osmania General Hospital
Hyderabad, Telangana, India
Yashoda Hospital
Secunderabad, Telangana, India
Nil Ratan Sircar Medical College & Hospital
Kolkata, West Bengal, India
Fondazione IRCCS CA Granda Ospedale Maggiore Policlinico
Milan, Lombardy, Italy
Azienda Ospedaliero Universitaria San Martino
Genova, , Italy
Seconda Università degli Studi di Napoli
Naples, , Italy
ICS Maugeri SpA SB
Pavia, , Italy
Kokura Memorial Hospital (Kokura Kinen Hospital)
Fukuoka, , Japan
Kanazawa University Hospital
Kanazawa, , Japan
Nara University
Kashihara, , Japan
St. Marianna University (SMU) School of Medicine
Kawasaki, , Japan
Niigata University
Niigata, , Japan
Okayama University Hospital
Okayama, , Japan
Osaka General Medical Center
Osaka, , Japan
Dokkyo Medical University - Saitama Medical Center
Saitama, , Japan
Showa University Hospital
Shinagawa-ku, , Japan
Juntendo Nerima Hospital
Tokyo, , Japan
Juntendo University Hospital, Tokyo
Tokyo, , Japan
Fujita Health University Hospital
Toyoake, , Japan
Juntendo University Urayasu Hospital
Urayasu, , Japan
Waikato Hospital
Hamilton, , New Zealand
Middlemore Clinical Trials
Papatoetoe, , New Zealand
Samodzielny Publiczny ZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego
Lodz, , Poland
Centrum Medyczne Medyk - Rzeszow
Rzeszów, , Poland
Miedzyleski Szpital Specjalistyczny
Warsaw, , Poland
Centro Hospitalar de Lisboa Ocidental EPE - Hospital Santa Cruz
Carnaxide, , Portugal
Centro Hospitalar do Medio Tejo (CHMT), E.P.E.
Torres Novas, , Portugal
Hallym University Medical Center
Anyang, , South Korea
Chungnam National University Hospital
Daejeon, , South Korea
Myongji Hospital
Gyeonggi-do, , South Korea
Seoul National University Bundang Hospital
Gyeonggi-do, , South Korea
Jeju National University Hospital
Jeju City, , South Korea
CHA Bundang Medical Center, CHA University
Seongnam-si, , South Korea
Korea University Anam Hospital
Seoul, , South Korea
Kyung Hee University Hospital at Gangdong
Seoul, , South Korea
Severance Hospital, Yonsei University Hospital
Seoul, , South Korea
Fundacion Puigvert
Barcelona, , Spain
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital Universitario 12 De Octubre
Madrid, , Spain
Hospital de Sagunto
Sagunto, , Spain
Hospital Universitario Virgen Macarena
Seville, , Spain
H U Dr. Peset
Valencia, , Spain
Changhua Christian Medical Foundation
Changhua, , Taiwan
National Taiwan University Hospital Hsin-Chu Branch
Hsinchu, , Taiwan
Far Eastern Memorial Hospital
New Taipei City, , Taiwan
Taipei Medical University
New Taipei City, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
North Bristol HNS Trust, Clinical Research Centre
Bristol, , United Kingdom
Lister Hospital
Hertford, , United Kingdom
Leicester General Hospital
Leicester, , United Kingdom
King's College Hospital
London, , United Kingdom
Guys Hospital
London, , United Kingdom
Royal London Hospital
London, , United Kingdom
Salford Royal
Salford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Heerspink HJL, Jardine M, Kohan DE, Lafayette RA, Levin A, Liew A, Zhang H, Lodha A, Gray T, Wang Y, Renfurm R, Barratt J; ALIGN Study Investigators. Atrasentan in Patients with IgA Nephropathy. N Engl J Med. 2025 Feb 6;392(6):544-554. doi: 10.1056/NEJMoa2409415. Epub 2024 Oct 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHK01-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.